| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_129e393582e6bdf4029baf2206522f45 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D489-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1688
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-10 |
| filingDate |
2008-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f6d43f9b186b538ac4446f1058cf930
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30e071f3f389d4166b8c09edcad1f0b9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56b80d4555a7f2fe48fca09f17ed0d31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74b6f2d3ccc2807deaeb1b4f54b2fc66 |
| publicationDate |
2010-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20100056424-A |
| titleOfInvention |
Crystalline micronized particles |
| abstract |
The present invention discloses crystalline particles of N- (17-cyclopropylmethyl-4,5α-epoxy-3,14-dihydroxy-morphinan-6β-yl) -phthalimide or a pharmaceutically acceptable salt thereof. It is. The crystalline particles have a particle diameter (D50) in the range of 1 to 30 µm at a point where the cumulative frequency of the volume distribution reaches 50% by accumulating from the particle having the smaller particle diameter, and from the particle having the smaller particle diameter. The particle diameter (D90) at the point where the cumulative frequency of the volume distribution reaches 90% cumulatively is 90 μm or less, and the crystallinity is 80% or more. According to the crystalline particles, it is possible to increase the bioavailability of the raw medicine while ensuring the storage stability of the compound. |
| priorityDate |
2007-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |